TEVA — Teva Pharmaceutical Industries Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareBalancedMicro Cap
Annual cashflow statement for Teva Pharmaceutical Industries, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 456 | -2,406 | -615 | -1,959 | 1,418 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 833 | 2,490 | 1,219 | 3,216 | 1,266 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,701 | 1,257 | -72 | -435 | -1,366 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | 798 | 1,590 | 1,368 | 1,247 | 1,649 |
| Capital Expenditures | -562 | -548 | -526 | -498 | -501 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 2,085 | 1,204 | 1,494 | 1,290 | 1,238 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1,523 | 656 | 968 | 792 | 737 |
| Financing Cash Flow Items | -6 | -118 | -212 | -150 | -337 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2,172 | -1,487 | -1,913 | -1,791 | -2,151 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21 | 636 | 393 | 74 | 256 |